Cancer is the world's second-deadliest disease which contributes towards the fatality of over 10 million people per year. Oncologists adopt a variety of treatment procedures to treat cancer cells. Among the different methods used to fight cancer, chemotherapeutic treatment is a prominent and well-adopted technique. It is a drug-based method, wherein powerful chemical compounds are injected into the body to annihilate the malignant cells. Although these chemicals support the destruction of cancerous cells, optimizing their dosage has always been a challenge to medical specialists.
Cisplatin is a chemotherapy medication that is used to treat several cancers such as lung cancer, brain tumor, breast cancer, liver cancer, etc. This platinum-metal-based chemotherapy drug is highly powerful and is instituted by the intravenous route into the body. Although it is renowned for the effective destruction of cancerous cells for the past 4 decades, its alarming side effects are of serious concern to the medical community.
Researchers have reported that administration of a high dosage of the chemical is not only ineffective on the tumor cells but is also responsible for adverse side effects which may even lead to the sudden demise of the patient. The control on the level of the cisplatin drug has been a matter of persisting concern for medical practitioners.
A recent study on monitoring the cisplatin level in liver cancer cells reported by researchers from the Graduate School of Medical and Dental Sciences at Niigata University, Japan, and their collaborators from Niigata Medical Center, Uonuma Institute of Community Medicine Niigata University Hospital, Niigata City General Hospital, Saiseikai Niigata Hospital and, Kashiwazaki General Hospital and Medical Center provides a ray of hope to the health professionals. The findings were published recently in the prestigious Scientific Reports journal from Nature publishing house.
The multi-disciplinary research team has identified adipose's most abundant 2 protein (APM2) as a potential marker to indicate the permissible level of the drug. They have experimentally investigated the liver and gastro cancer cells and have compared the variation in the protein concentration in the presence and absence of the chemo drug.
The research study paves way for effective monitoring of chemotherapeutic drug levels and their safe administration. Professor Kenya Kamimura states with confidence that, "The serum APM2 can be an effective biomarker of the liver and gastric cancer cells for determining the sensitivity to cisplatin. The results of the study would provide an advantage for the technicians, allowing easy adaption in small local clinics."
The research group has noticed that APM2 concentration favors the development of ERCC6L gene cards. This is manifested by the growth of the cancerous cells and marks the resistance to the chemo drug. The valuable findings offer the potential to control the cisplatin dosage level and avoid cytotoxicity. Such a study is essential in today's context as research groups across the globe strive to develop new methodologies to optimize the dosage and control the severe side-effects induced by the concentration of chemo drugs. The research team has also utilized bioinformatics-based tools to complement the experimentally obtained results.
"To the best of our knowledge, this is the first report to demonstrate that the serum level of APM2 can be the predictor of the CDDP chemosensitivity. This study thus represents a milestone for detecting CDDP sensitivity, and further studies will help modify APM2 expression, which could contribute to the chemosensitization of the tumor" describes Professor Kenya Kamimura.
The interesting results of the research study have laid a foundation to track the chemo drug level. Future studies will explore the mechanism and relation between APM2 and ERCC6L. Such studies are in the cutting-edge research areas of oncological sciences and hold immense potential in further extending the results to other types of cancers.